LAUSR

Background: bone morphogenetic proteins are responsible for activating mesenchymal stem cells into osteocytes. This effect is signaled by serine-threonine kinase receptors called bone morphogenetic protein receptors. BMPR1A and BMPR2 polymorphisms were not reported to be associated with bone healing process. The objective of this study was to investigate BMP-2/-7 heterodimer and BMPR1A/ BMPR2 polymorphism with fracture healing progress. Subjects and Methods: This is a case-control study conducted in selected hospitals in Khartoum, Sudan. Blood samples were taken from patients and healthy controls. Followed by clinical examination until the point of functional recovery. Quantitative ELISA and protein-pull down assay were done to BMP-2 and BMP-7. Genomic DNA extraction and PCR/RFP and sequencing were done to BMPR1A and BMPR2 target sequences. Results: Matched case and control groups in age and gender. Functional outcome regained after 4.1 months ± 2.6. BMP2/7 complex levels were 288.75pg/ml ± 266.8 and 532.23 pg/ml ±582.5 in case and control, respectively (p= 0.021). BMPR2 exhibited single nucleotide polymorphism among all participants; while there was 25% and 22% had variant [A] BMPR1A, 75% and 78% [T] variant BMPR1A in case and control, respectively. Conclusion: Significant change in plasma BMP-2/-7 heterodimer concentration was observed after trauma but no significant correlation between BMPR1A and BMPR2 polymorphism with fracture healing.